US2014120038A1PendingUtilityA1
Nanoparticles for imaging and treating chlamydial infection
Est. expiryJul 24, 2027(~1 yrs left)· nominal 20-yr term from priority
A61K 31/496A61K 31/49A61K 47/6937A61K 47/551A61K 47/6921A61K 31/7052A61K 31/519A61K 47/22A61K 47/6935A61K 49/0093A61K 47/48869
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against Chlamydia.
Claims
exact text as granted — not AI-modified1 - 5 . (canceled)
6 . A composition comprising nanoparticles conjugated with folic acid, wherein said particles comprise a first antibiotic in a form and in a dosage suitable for treatment of a persistent intracellular Chlamydia infection wherein Chlamydia of said infection lack ftsK transcription or lack ftsK and ftsW transcription at the time the composition is administered.
7 . The composition of claim 6 comprising nanoparticles conjugated with folic acid, wherein said particles further comprise one or more other antibiotic(s) active against persistent intracellular Chlamydia infection.
8 . The composition of claim 6 , wherein said first antibiotic is selected from the group consisting of azithromycin, amoxicillin, rifampicin, erythromycin, erythromycin ethylsuccinate, ofloxacin, levofloxacin doxycycline, and tetracycline.
9 . The composition of claim 7 , wherein said one or more other antibiotics is selected from the group consisting of azithromycin, amoxicillin, rifampicin, erythromycin, erythromycin ethylsuccinate, ofloxacin, levofloxacin doxycycline, and tetracycline, and said one or more other antibiotics is different from said first antibiotic.
10 - 12 . (canceled)
13 . A composition for imaging persistent intracellular Chlamydia infection in a cell, comprising nanoparticles conjugated with folic acid, wherein said nanoparticles further comprise at least one detectably labeled moiety and wherein Chlamydia of said infection lack ftsK transcription or lack ftsK and ftsW transcription at the time of imaging.
14 . The composition of claim 13 , wherein said nanoparticles are fluorescently labeled.Join the waitlist — get patent alerts
Track US2014120038A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.